TIDMEDEN
RNS Number : 3482O
Eden Research plc
29 May 2020
29 May 2020
Eden Research Plc
("Eden" or "Company")
Issuing of Annual Report & Notice of AGM
Eden Research plc (AIM: EDEN), the AIM listed company that
develops and supplies breakthrough biopesticide products and
natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries,
announces that its Annual Report and Accounts for the year ended 31
December 2019 and Notice of the Annual General Meeting ("AGM") have
been issued to shareholders and are now available on the Company's
website: www.edenresearch.com
The AGM is to be held on Wednesday 24 June 2020 at 12.00pm at 6
Priory Court, Priory Court Business Park, Poulton, Cirencester,
Gloucestershire, GL7 5JB . Given the COVID-19 restrictions, it is
no longer possible to hold the AGM in the way that the Board had
planned and therefore regrettably we cannot allow shareholders to
attend in person and the Company's Articles of Association do not
currently permit hybrid or virtual meetings.
In accordance with current Government regulations in relation to
COVID-19, shareholders are encouraged to submit their Form of Proxy
in advance of the General Meeting, as to attend the General Meeting
in person would, as at the date of this announcement, be
inconsistent with the relevant regulations. Shareholders who
attempt to attend the General Meeting in person in breach of the
stay at home measures will not be admitted.
Should Shareholders wish to ask any questions in relation to the
Resolutions, which they may otherwise have asked at the AGM, had
they been in attendance, they are encouraged to contact the Company
prior to the AGM by
email at agm@edenresearch.com so as to be received no later than 23 June 2020.
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Cenkos Securities (Nominated advisor and
broker)
Giles Balleny / Cameron MacRitchie (corporate
finance)
Michael Johnson (sales) 020 7397 8900
Hawthorn Advisors
Lorna Cobbett 020 3745 4960
Jana Tsiligiannis eden@hawthornadvisors.com
Notes:
Eden Research is an AIM listed company that develops and
supplies breakthrough biopesticide products and natural
microencapsulation technologies to the global crop protection,
animal health and consumer products industries
Eden's Sustaine ä encapsulation technology harnesses the
biocidal efficacy of naturally occurring chemicals produced by
plants (terpenes) and can be used with both natural and synthetic
compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free,
biodegradable micro-spheres derived from yeast extract. They
produce stabilised aqueous suspensions which, are easy to mix and
apply, have phased release patterns, are safer for the environment
and the crops themselves.
The European Chemicals Agency (ECHA) has proposed an EU-wide
restriction on the placing on the market or use of
"intentionally-added" microplastic particles. The proposed
restriction includes the use of microplastics for agricultural and
horticultural purposes, including polymers utilized for
controlled-release fertilizers, encapsulated plant protection
products (PPPs), seed coatings, and biocides.
By 2025 in the EU, pesticides containing synthetic polymer
microplastics are likely to be banned and removed from the market.
The only acceptable alternative is the substitution with
biodegradable formulations. Reformulated products will need to be
evaluated and registered within the five-year transition
period.
Sustaine is one of the only viable, proven and immediately
registerable solutions to the microplastics problem in formulations
requiring encapsulation.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Sustaine provides a unique, environmentally friendly
solution to these problems and enables terpenes to be used as
effective, low-risk agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP14m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, Mevalone, were approved as new ingredients for
use in plant protection products by the European Commission ("EC").
This represented a major milestone in the commercialisation of
Eden's technology and is a significant accomplishment for any
company. To illustrate this point, one should note that in 2013,
Eden's approvals represented 3 of only 10 new active ingredients
approved by the EC.
Mevalone ä is a foliar fungicide which has been authorised for
sale in Kenya, Malta, Greece, Bulgaria,
Spain, Italy, France, Cyprus, Albania , Portugal and Macedonia.
Cedroz ä is a nematicide which has been authorised for sale in
Malta, Belgium and Mexico.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com .
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAKZGZKVLVGGZG
(END) Dow Jones Newswires
May 29, 2020 02:58 ET (06:58 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2023 to Apr 2024